Abstract:Extracellular matrix (ECM) stiffening, resulting from increased collagen deposition and cross-linking, is a key biophysical factor of the tumor microenvironment. Cutaneous melanoma is a deadly metastatic cancer. Its aggressiveness stems from high intratumoral heterogeneity, resulting from the plasticity of melanoma cells, which transit from a melanocytic state to dedifferentiated therapy-resistant and invasive phenotypes, characterized by mesenchymal and/or neural crest stem cell-like features. Phenotypic plasticity is regulated by stroma-derived soluble factors, but the functional impact of ECM stiffening on melanoma cell phenotypes remains ill defined. Here, we found that melanoma cell subpopulations display difference in mechanical responsiveness. Compared to melanocytic cells, mesenchymal dedifferentiated cells showed increased proliferation, migration and resistance to MAP kinase-targeted therapy when seeded on stiff collagen. By contrast, a soft ECM impaired their proliferation and migration and sensitized them to targeted therapy. In addition, extracellular mechanical signals are required to sustain melanoma cell identity and dedifferentiation features. Further analyses indicated that the mechanosensitivity nature of dedifferentiated cells relies on the expression and activation of collagen receptors DDR1 and DDR2 that control actomyosin cytoskeleton reorganization and YAP mechanotransduction pathway. Inhibiting both DDR in dedifferentiated melanoma cells abrogated their mechano-induced behavior and drug-resistant phenotype, while forcing their expression in melanocytic cells induced mechanical responsiveness and a less differentiated phenotype. Our results reveal that phenotypic reprogramming endows dedifferentiated melanoma cells with increased sensitivity and addiction to ECM stiffness. We propose that mechano-addiction mediated by DDR collagen receptors may represent a novel vulnerability for aggressive dedifferentiated cancer cells that can be exploited for therapeutic benefits.

Extracellular matrix stiffness determines DNA repair efficiency and cellular sensitivity to genotoxic agents

Extracellular Matrix Stiffness Regulates DNA Methylation by PKCα‐Dependent Nuclear Transport of DNMT3L (adv. Healthcare Mater. 16/2021)

Extracellular Matrix Stiffness Regulates Dna Methylatioan By Pkc Alpha-Dependent Nuclear Transport Of Dnmt3l

Extracellular Matrix Stiffness Regulates DNA Methylation by PKC α ‐Dependent Nuclear Transport of DNMT3L

DNA damage alters nuclear mechanics through chromatin reorganization

Linking Oxidative Stress and DNA Damage to Changes in the Expression of Extracellular Matrix Components

Matrix Stiffness Determines the Phenotype of Vascular Smooth Muscle Cell in Vitro and in Vivo: Role of DNA Methyltransferase 1

Matrix Stiffness Exacerbates the Proinflammatory Responses of Vascular Smooth Muscle Cell Through the DDR1-DNMT1 Mechanotransduction Axis.

Matrix stiffness regulates α-TAT1-mediated acetylation of α-tubulin and promotes silica-induced epithelial–mesenchymal transition via DNA damage

Effects of TET2-mediated methylation reconstruction on A2058 melanoma cell sensitivity to matrix stiffness in a 3D culture system

Increased Matrix Stiffness Promotes Fibrogenesis of Hepatic Stellate Cells Through AP-1-induced Chromatin Priming

Regulation of Nuclear Mechanics and the Impact on DNA Damage

Insights into the mechanisms, regulation, and therapeutic implications of extracellular matrix stiffness in cancer

Biphasic regulation of epigenetic state by matrix stiffness during cell reprogramming

The Role of Matrix Stiffness in Cancer Stromal Cell Fate and Targeting Therapeutic Strategies

Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin

Deciphering stiffness-driven changes in colorectal cancer by proteomics

Extracellular matrix stiffness determines the phenotypic behavior of dedifferentiated melanoma cells through a DDR1/2-dependent YAP mechanotransduction pathway

The Matrix Stiffness Coordinates the Cell Proliferation and PD-L1 Expression via YAP in Lung Adenocarcinoma

Genetic variation drives cancer cell adaptation to ECM stiffness